Pharmafile Logo
Pharmafocus logo
Advanced Search

depression

Showing 15 posts of 52 posts found.

NICE recommends nine digital treatment options for depression and anxiety

May 17, 2023
Medical Communications NICE, Neurology, anxiety, depression, digital health, mental health

The National Institute for Health and Care Excellence (NICE) has recommended six digitally enabled therapies for adult patients with anxiety …

News

Perception and Otsuka enter collaboration and licensing deal for depression drug candidate

March 16, 2021
Manufacturing and Production CNS, Otsuka Pharmaceutical, Perception Neuroscience, depression

Perception Neuroscience and Otsuka Pharmaceutical have announced a collaboration and licensing agreement for the development and commercialisation of Perception’s lead …

News
spravato

Janssen’s esketamine nasal spray secures CHMP recommendation in Europe for the rapid reduction of depressive symptoms in a psychiatric emergency for patients with major depressive disorder

December 11, 2020
Medical Communications EMA, Europe, Spravato, depression

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has moved to recommend Janssen’s …

News

NICE knocks back Janssen’s Spravato nasal spray for the second time in treatment-resistant depression

September 3, 2020
Sales and Marketing Janssen, Spravato, depression, pharma

NICE has opted to reject Janssen’s nasal spray Spravato (esketamine) for routine use on the NHS for treatment-resistant major depressive …

News
janssen_latest_logo_on_sign

FDA expands approval for Janssen’s Spravato nasal spray to cover major depressive disorder with suicidal ideation

August 4, 2020
Manufacturing and Production FDA Janssen, Spravato, depression

The FDA has moved to expand the existing approval of Janssen’s Spravato (esketamine) CIII nasal spray to include treatment of symptoms …

News

Axsome’s late-stage study of experimental depression drug misses main trial goal

March 31, 2020
Manufacturing and Production Depressive Disorder, MDD, depression, migraine

Axsome Therapeutics reported on Monday that its Phase 3 study of its experimental depression drug missed its main trial goal. …

News
janssen_latest_logo_on_sign

NICE rejects Janssen’s esketamine nasal spray Spravato for treatment-resistant depression

January 28, 2020
Manufacturing and Production, Sales and Marketing Janssen, NHS, NICE, Spravato, depression

Janssen’s Spravato (esketamine) nasal spray, derived from the party drug ketamine, has been turned down by NICE for NHS use …

News
janssen_latest_logo_on_sign

European Commission authorises Janssen’s anti-depressant Spravato

December 23, 2019
Sales and Marketing Janssen, MDD, Nasal Spray, TRD, depression, mental health

The European Commission has approved Janssen’s nasal spray Spravato (esketamine), which is used to treat major depressive disorder (MDD) that …

News

Oral contraceptive use as teenager linked to depression as an adult, study says

August 29, 2019
Research and Development MDD, depression, hormones, oral contraceptives, psychiatry, psychology

Women who have used oral contraceptives as teenagers are more likely to experience depression later in life, according to a …

News
spravato

Janssen’s argues for the cost-effectiveness of Spravato in treatment-resistant depression

May 23, 2019
Sales and Marketing FDA, Janssen, depression, major depressive disorder, pharma, treatment-resistant depression

Janssen has unveiled a new cost-effectiveness analysis for its recently FDA-approved nasal spray Spravato (esketamine) in the treatment of treatment-resistant …

News
spravato

New Phase 3 data backs up the efficacy of esketamine in treatment-resistant depression

May 21, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Spravato, depression, esketamine, pharma

New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the …

News
shutterstock_57369385

England’s antidepressant prescriptions double to 70m in a decade

March 29, 2019
Medical Communications England, UK, antidepressants, anxiety, depression, pharma

Figures released by NHS Digital have revealed that prescriptions for antidepressants in the UK have risen to 70.9 million, almost …

News
5789851635_d493d41b35_z

Department of Veteran Affairs to offer Janssen’s esketamine to veterans with depression

March 21, 2019
Medical Communications Jannsen, Spravato, VA, depression, esketamine, military, veteran affairs

The United States Department of Veteran Affairs (VA), the federal agency responsible for providing healthcare services to military veterans, is …

News

FDA approves first-ever postpartum depression therapy: Sage Therapeutics’ Zulresso

March 20, 2019
Research and Development, Sales and Marketing FDA, Sage Therapeutics, depression, pharma, postpartum depression

The FDA has announced its decision to approve Sage Therapeutics’ intraveneous injection Zulresso (brexanolone), marking the first authorisation of a …

News
allergan

Allergan’s depression drug rapastinel fails to outperform placebo at Phase 3

March 7, 2019
Research and Development Allergan, FDA, depression, major depressive disorder, pharma, rapastinel

As Janssen celebrated the FDA approval of the first novel therapy for depression in three decades with Spravato, Allergan released …

News

Latest content

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024